News | September 25, 2022
Aptar Pharma collaborates with Fluidda
The companies will leverage their respective proprietary technology platforms
The companies will leverage their respective proprietary technology platforms
The company has received payment towards completion of sale of the first tranche from Sekhmet Pharmaventures Private Limited.
To set up 50 lifestyle modification centres across the UAE in the next 24 months
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Subscribe To Our Newsletter & Stay Updated
